Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; CONICET - Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigaciones en Producción Animal (INPA), Buenos Aires, Argentina. Electronic address: mribicich@fvet.uba.ar.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; CONICET - Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigaciones en Producción Animal (INPA), Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; Servicio Nacional de Sanidad Animal, SENASA, Argentina.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; CONICET - Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigaciones en Producción Animal (INPA), Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; CONICET - Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigaciones en Producción Animal (INPA), Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Cátedra de Parasitología y Enfermedades Parasitarias, Av. San Martín 5285 (1417DSM), Buenos Aires, Argentina; CONICET - Universidad de Buenos Aires, Facultad de Ciencias Veterinarias, Instituto de Investigaciones en Producción Animal (INPA), Buenos Aires, Argentina.
Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
Department of Public Health, Health Promotion and Disease Prevention Research Group (Grupo de Investigación Promoción de la Salud y Prevención de la Enfermedad - GIPSPE), Universidad de Caldas, Manizales, Colombia.
Postgraduate Program in Animal Science in the Tropics, Federal University of Bahia, Salvador, Bahia, CEP: 40170-110, Brazil. Electronic address: franklinrietcorrea@gmail.com.
Universidad Católica de Salta. Facultad de ciencias agrarias y veterinarias; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET); Área de Sanidad Animal "Dr. Bernardo Jorge Carrillo"-Instituto de Investigación Animal Chaco Semiárido (Sede Salta) CIAP-INTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA. (INTA).
Plataforma de Investigación en Salud Animal (PSA), Instituto Nacional de Investigación Agropecuaria (INIA), Estación Experimental del Norte, Tacuarembó, 45000, Uruguay.
Laboratorio de Anatomía Comparada y Evolución de los Vertebrados, Museo Argentino de Ciencias Naturales "Bernardino Rivadavia" (CONICET); Av. Ángel Gallardo 470, C1405DJR Ciudad Autónoma de, Buenos Aires, Argentina. nicochimento@hotmail.com.
Laboratorio de Anatomía Comparada y Evolución de los Vertebrados, Museo Argentino de Ciencias Naturales "Bernardino Rivadavia" (CONICET); Av. Ángel Gallardo 470, C1405DJR Ciudad Autónoma de, Buenos Aires, Argentina.
Fundación de Historia Natural "Félix de Azara", Departamento de Ciencias Naturales y Antropología, CEBBAD - Universidad Maimónides, Hidalgo 767, C1405BDB, Buenos Aires, Argentina.
Laboratorio de Anatomía Comparada y Evolución de los Vertebrados, Museo Argentino de Ciencias Naturales "Bernardino Rivadavia" (CONICET); Av. Ángel Gallardo 470, C1405DJR Ciudad Autónoma de, Buenos Aires, Argentina.
For the purpose of a better understanding of enteric hyperoxaluria in Crohn's disease (CD) in children and adolescents, we investigated the occurrence and risk factors for development of hyperoxaluria...
Forty-five children with CD and another 45 controls were involved in this cross-sectional study. Urine samples were collected for measurement of spot urine calcium/creatinine (Ur Ca/Cr), oxalate/creat...
According to the activity index, 30 patients (66.7%) had mild disease and 13 patients (28.9%) had moderate disease. There was no significant difference in Ur Ox/Cr ratio regarding the disease activity...
Lack of intestinal colonization with O. formigenes, steatorrhea, and frequent stools are the main risk factors for development of enteric hyperoxaluria in CD patients. Identifying risk factors facilit...
Hyperoxaluria is a clinically relevant metabolic entity that portends a high morbidity burden. Primarily manifesting as kidney stone disease and chronic kidney disease, advanced hyperoxaluria can also...
Hallmarks of primary hyperoxaluria type 3 are nephrolithiasis and hyperoxaluria. However, little is known about factors influencing stone formation in this disease. We characterized stone events and e...
We retrospectively analyzed clinical, and laboratory data of 70 primary hyperoxaluria type 3 patients enrolled in the Rare Kidney Stone Consortium Primary Hyperoxaluria Registry....
Kidney stones occurred in 65/70 primary hyperoxaluria type 3 patients (93%). Among the 49 patients with imaging available, the median (IQR) number of stones was 4 (2, 5), with largest stone 7 mm (4, 1...
Stones impose a lifelong burden on primary hyperoxaluria type 3 patients. Reducing urinary calcium oxalate supersaturation may reduce event frequency and surgical intervention....
Primary hyperoxaluria (PH) results from genetic mutations in different genes of glyoxylate metabolism, which cause significant increases in production of oxalate by the liver. This study aimed to repo...
A single-center observational cohort study was conducted at Children's University Hospital in Damascus, and included all patients admitted from 2018 to 2020, with a diagnosis of hyperoxaluria (urinary...
The study included 100 patients with hyperoxaluria, with slight male dominance (57%), and median age 1.75 years (range, 1 month-14 years). Initial complaint was urolithiasis or nephrocalcinosis in 47%...
PH1 is still a grave disease with wide variety of clinical presentations which frequent results in delays in diagnosis, thus kidney failure is still a common presentation. In Syria, we face many chall...
Autosomal recessive disorders are prevalent in Pakistan, a developing South Asian country where consanguineous marriages are common. This study seeks to determine the prevalence of monogenic causes in...
Nedosiran is an investigational RNA interference agent designed to inhibit expression of hepatic lactate dehydrogenase, the enzyme thought responsible for the terminal step of oxalate synthesis. Oxala...
Based on the single-center case reports and all reported patients with primary hyperoxaluria type 1 (PH1) in China, this study discussed the clinical and genetic characteristics of this disease retros...
Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacoki...
Phase 3, open-label, single-arm trial....
Multinational study; enrolled patients with PH1 of all ages, estimated glomerular filtration rate ≤45 mL/min/1.73 m...
Lumasiran administered subcutaneously; 3 monthly doses followed by monthly or quarterly weight-based dosing....
Primary end point: percent change in POx from baseline to month 6 (cohort A; not receiving hemodialysis at enrollment) and percent change in predialysis POx from baseline to month 6 (cohort B; receivi...
All patients (N = 21; 43% female; 76% White) completed the 6-month primary analysis period. Median age at consent was 8 (range, 0-59) years. For the primary end point, least-squares mean reductions in...
Single-arm study without placebo control....
Lumasiran resulted in substantial reductions in POx with acceptable safety in patients with PH1 who have advanced kidney disease, supporting its efficacy and safety in this patient population....
Alnylam Pharmaceuticals....
Registered at ClinicalTrials.gov with study number NCT04152200 and at EudraCT with study number 2019-001346-17....
Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by excessive hepatic oxalate production that frequently causes kidney failure. Lumasiran is an RNA interference therapeutic t...
This study investigated the risk profile and the impact of dietary intervention in calcium oxalate stone formers with enteric hyperoxaluria under controlled, standardized conditions. Thirty-seven pati...
We report the case of a 12-year-old boy with primary hyperoxaluria type 2 (PH2) presenting with end-stage renal disease and systemic oxalosis who underwent a combined living donor liver and kidney tra...